Lyra Therapeutics, Inc.

LYRA Nasdaq CIK: 0001327273

Company Information

Industry Surgical & Medical Instruments & Apparatus
SIC Code 3841
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address 480 ARSENAL WAY, WATERTOWN, MA, 02472
Mailing Address 480 ARSENAL WAY, WATERTOWN, MA, 02472
Phone 617-373-4600
Fiscal Year End 1231
EIN 000000000

Financial Overview

FY2024

-$62.68M
Net Income
$54.75M
Total Liabilities
$40.58M
Cash & Equivalents
$-1.26
EPS

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events February 6, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) January 20, 2026 View on SEC
8-K Current report of material events January 12, 2026 View on SEC
4 Insider stock transaction report January 8, 2026 View on SEC
4 Insider stock transaction report January 8, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment November 25, 2025 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment November 18, 2025 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment November 13, 2025 View on SEC
4 Insider stock transaction report November 13, 2025 View on SEC
8-K Current report of material events November 12, 2025 View on SEC

Material Events

8-K Financial Distress February 6, 2026
High Impact
  • Nasdaq issued a delisting notice, classifying Lyra Therapeutics as a "public shell."
  • The company halted development of its main drug candidate, LYR-210, due to severe financial problems and lack of funding.
View Analysis

Insider Trading

SELL 2 insiders 2 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 3841)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.